We will be present at SIBS in Zurich, the international conference on Image-Based Screening. The program is plenty of interesting talks on “model systems in screening”, “advances in screening technology and assay”, or “images and data analysis”.

Furthermore, Nathalie, our CEO, is invited to present our activities on phenotypic screening on our innovative 3D culture assays. She will present you our activities, especially on our advances regarding the differentiation of patient-derived induced pluripotent stem cells for phenotypic screening in metabolic diseases. Furthermore, she will explain our vision on how new technologies, as virtual and augmented realities, deep learning and machine learning can be an advantage in phenotypic screening.

Nathalie hopes to see you in this congress to discuss on these topics! If you want to schedule a appointment, contact us.

As last year, we will be very happy to attend Drug Discovery 2017 event in Liverpool (Innovation Zone, IZ1 booth). We will present our activities, the new assays that we have developed recently and our brand new robotic platform.

“Drug Discovery is ELRIG’s flagship event. Now in its 11th year, we return to ACC in Liverpool to bring together the leading lights in drug discovery research across pharma, biotech, academia and the vendor community.”

As you can see on the dedicated webpage, the event program is highly interesting:

  • Advances in Imaging
  • Drug Discovery in the 4th Dimension
  • Innovations in Assay Design, Development and Screening

And of course, don’t forget the amazing “Innovation Zone”, the right place to discover future partners, as HCS Pharma !

Come and join us in Drug Discovery 2017 in the Innovation Zone at booth IZ1, to discuss with Nathalie, our CEO and Pierre-Jean, our in vitro toxicology expert !

Nathalie will be present tuesday 3 October, 3-4 pm, on booth of our partner Molecular Devices (#D18) to answer your high-content screening (HCS) questions.  Book a time slot to meet Nathalie !

During these last two weeks, we took control of our new robotic platform and validated the pipetting volumes and the entire process by testing it with a few plates. Some steps are still to be improved, such as the scheduling of the plates. The first screening with a few plates was on hepatotoxicity assay on SCREEN-WELL® Hepatotoxicity library from ENZO (238 compounds) in one concentration.

After improving our process, we will test this library in dose effect in addition to the Prestwick library. We will also perform neurotoxicity assay in a screening mode on internal and Prestwick library. These assays will allow us to validate all our process to cell culture until data analysis in addition to exemplify data on our toxicity assays.

In-Cosmetics Paris, April 12 to 14

Come and visit us at in-cosmetics, the meeting of the major groups of cosmetics, Porte de Versailles in Paris.

We will exhibit Stand P43 within the Cosmetic Valley in partnership with Bretagne Commerce International.

We will be happy to welcome and present you our services in phenotypic screening and cell imaging.

Do you know what is phenotypic screening ? If you are here I think yes 🙂 But if you want to explain it easily, I strongly recommend the reading of Perkin Elmer white paper « Phenotypic Drug Discovery with High Content Screening ». It’s short (only 4 pages) but it contents main information to understand differences between « target based » and « phenotypic screening » approaches in drug discovery.

It explains also the importance of the technology side and the digital side of HCS and finally, give a good summarize of our vision :

“Today’s drug discovery strategies require candidate compounds to fail early and cheaply in the discovery stage, rather than late and expensively in the clinical phase. Testing compounds from the beginning in physiologically relevant model systems and leveraging the rich information available in image-based screens are ways to focus on those compounds that give rise to the right phenotypic changes without undesirable effects on the system. High Content Screening with highly detailed multiparametric assays in conjunction with modern machine-learning tools provide a promising way to achieve this goal.”

 Source : http://go.perkinelmer.com/Q315-WhitePaperEmailPKI-INF-LP?cid=4296

HCA/HCS assays are now realised on cell models which are more and more complex as 3D and/or co-culture. And to be more relevant, imaging assay in low/medium troughput can also be performed on whole organism as zebrafish. Here is an interesting video from Department of Biological Sciences, University of Notre Dame, explaining how to do imaging on zebrafish embryos.

The zebrafish is an excellent experimental organism to study vertebrate developmental processes and model human disease. Here, we describe a protocol on how to perform a manual high-throughput chemical screen in zebrafish embryos with a whole-mount hybridization (WISH) read-out.

Curated from www.jove.com

%d bloggers like this: